Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 121,474 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: Autism Spectrum Disorder
Interventions: No Intervention; Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 3 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts • Toms River, New Jersey • Durham, North Carolina

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Atomoxetine Hydrochloride; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Cancer
Interventions: TLC178; Drug
Lead sponsor: Taiwan Liposome Company; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Detroit, Michigan • The Bronx, New York

Conditions: Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: Pacritinib, Cytarabine, Daunorubicin Hydrochloride, Decitabine, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: Bhavana Bhatnagar; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Post-stroke Spasticity of the Lower Limb
Interventions: IncobotulinumtoxinA (400 Units), Placebo Comparator; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 12
States / cities: Downey, California • Long Beach, California • Fairfield, Connecticut + 9 more

Conditions: Cancer of the Cervix
Interventions: Granisetron, Ondansetron, Questionnaires, Study Drug Diary; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Metabolic Syndrome X, Prediabetic State, Insulin Resistance, Obesity, Metabolic Diseases
Interventions: Dietary supplement for weight loss, Education and counseling for weight loss; Drug · Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Carcinoma, Renal Cell
Interventions: TroVax, IL-2; Biological · Drug
Lead sponsor: Oxford BioMedica; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Traumatic Brain Injury (TBI), Chronic Traumatic Encephalopathy (CTE)
Interventions: Fish Oil (DPA+EPA 2:1 ratio) Capsules, High Oleic Safflower Oil Capsules; Dietary Supplement
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 25 Years · Male only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Brain Injury, Chronic, Brain Injuries, Traumatic
Interventions: Inulin fructooligosaccharide; Dietary Supplement
Lead sponsor: Centre for Neuro Skills; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bakersfield, California

Conditions: Health Behavior, Healthy
Interventions: The Stanford Active Choices program, The TLC system; Behavioral
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 55 Years and older
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Stanford, California

Conditions: Melanoma
Interventions: High-resolution contrast-enhanced MRI scan; Procedure
Lead sponsor: Redwood Regional Medical Group; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Sebastopol, California

Conditions: Metastatic Melanoma
Interventions: tasisulam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Lakeland, Florida + 5 more

Conditions: Pain, Nausea, Vomiting
Interventions: CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg), Placebo, Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg); Drug
Lead sponsor: Joseph Hazelton; Industry
Eligibility: 18 Years and older
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Musculoskeletal Disease, Sprains, Sprains and Strains, Injuries, Emergencies, Trauma, Acute Pain
Interventions: Ibuprofen, Lidocaine Patch 4%; Drug
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions: Not listed
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: 6 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Induction of Labor
Interventions: Misoprostol; Drug
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Psoriasis
Interventions: CP-690,550, Placebo/CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 44
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Bakersfield, California + 33 more

Conditions: Opioid Use Disorder
Interventions: naltrexone implant; Drug
Lead sponsor: Go Medical Industries Pty Ltd; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Accidental Fall, Patient Safety, Hospital Acquired Condition, Clinical Alarms, Mentoring
Interventions: High Intensity Coaching, Low Intensity Coaching; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Downey, California • Mountain View, California • Sacramento, California + 17 more

Conditions: Blepharitis
Interventions: AzaSite®; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Lynbrook, New York

Conditions: Cardiac Arrythmias, Syncope, Atrial Fibrillation, Atrial Flutter, Tachycardia, Stroke
Interventions: Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM; Device
Lead sponsor: Sparrow Clinical Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Lansing, Michigan • Traverse City, Michigan

Conditions: Age-Related Macular Degeneration
Interventions: PST, ST; Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 65 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Nutritional Deficiency
Interventions: Education on Female Athlete Nutritional Concerns; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

Study to Evaluate the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder

Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine

Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy

Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome

Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma

The Effects of Fish Oil Supplementation on the Brain Health of Collegiate Football Athletes

Traumatic Brain Injury and the Gut Microbiome

The CHAT (Community Health Advice by Telephone) Study

High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes

A Study of Tasisulam in Treating Participants With Malignant Melanoma

A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)

Efficacy of Lidocaine Patch in Acute Musculoskeletal Pain in the Emergency Department

Studies of Measures of Attention

Buccal Versus Vaginal Misoprostol In Combination With Foley Bulb

A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

The O'Neil Long Acting Naltrexone Implant (OLANI) Pharmacokinetic (PK)/Safety Study in Healthy Volunteers

Choosing Wisely: De-implementing Fall Prevention Alarms in Hospitals

Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis

Confirm Rx™ Versus Reveal LINQ™ - Which is More Reliable in Data Transmission? A Randomized Clinical Study

Improving Function in Age-Related Macular Degeneration

Knowledge of Nutritional Concerns in Physically Active Females